Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis

Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis

The aim of this review was to study the evidence base for the efficacy and safety of the P2Y12 receptor blocker ticagrelor in combination with acetylsalicylic acid in patients with stable coronary artery disease and high and moderate risk of adverse cardiovascular events. Currently, the mortality ra...

Full description

Bibliographic Details
Main Author:	T. N. Novikova
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-09-01
Series:	Российский кардиологический журнал
Subjects:	stable coronary artery disease high and moderate risk of cardiovascular events dual antiplatelet therapy ticagrelor
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4094

Similar Items

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
by: Ziwei Xi, et al.
Published: (2021-11-01)

Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
by: Chen Ning, et al.
Published: (2024-03-01)

Real-World Use of Clopidogrel and Ticagrelor in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries: Patient Characteristics and Long-Term Outcomes
by: Side Gao, et al.
Published: (2021-12-01)

Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study
by: Meng S, et al.
Published: (2022-04-01)

Age‐Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial
by: Byung Gyu Kim, et al.
Published: (2021-12-01)

Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study
by: Luigi Fiocca, et al.
Published: (2022-10-01)

Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study
by: Hua Yan, et al.
Published: (2020-06-01)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
by: Fan ZG, et al.
Published: (2019-02-01)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
by: Francesco Condello, et al.
Published: (2021-11-01)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01)

Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
by: Xiaojun Zhuo, et al.
Published: (2018-09-01)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01)

Body mass index affecting ticagrelor monotherapy vs. ticagrelor with aspirin in patients with acute coronary syndrome: A pre-specified sub-analysis of the TICO randomized trial
by: Byung Gyu Kim, et al.
Published: (2023-03-01)

Factors Determining Ticagrelor-Induced Dyspnea in Patients with Acute Coronary Syndrome
by: Vytenis Tamakauskas, et al.
Published: (2022-10-01)

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention
by: Moazez J. Marian, et al.
Published: (2017-11-01)

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
by: Ana Lucrecia Marcano, et al.
Published: (2022-11-01)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
by: Jialun Han, et al.
Published: (2023-03-01)

A Case of Ticagrelor Resistance
by: Jahanzeb Malik
Published: (2021-07-01)

A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization
by: Raffaele De Caterina, et al.
Published: (2022-04-01)

Association of ADP-Induced Whole-Blood Platelet Aggregation with Serum Low-Density Lipoprotein Cholesterol in Patients with Coronary Artery Disease When Receiving Maintenance Ticagrelor-Based Dual Antiplatelet Therapy
by: Bernadeta Chyrchel, et al.
Published: (2023-07-01)

Effect of ticagrelor versus clopidogrel after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome—propensity score matching analysis
by: Yinan Zhao, et al.
Published: (2024-01-01)

Comparison of In-Hospital Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Treated with Ticagrelor or Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study
by: Po-Yao Huang, et al.
Published: (2023-08-01)

Clinical implication of ticagrelor monotherapy in patients with small vessel coronary artery disease: results from the TICO randomized trial
by: Jae Young Cho, et al.
Published: (2023-08-01)

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry
by: Ziwei Xi, et al.
Published: (2022-11-01)

ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE
by: S. R. Gilyarevskiy, et al.
Published: (2015-12-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Incidence and impact of antiplatelet therapy cessation among very older patients with stable coronary artery disease
by: Xiao Zou, et al.
Published: (2023-06-01)

Implementation of Ticagrelor Reduced Mortality in Routine Clinical Care: Evidence From a Natural Experiment Including 109 995 Patients With Myocardial Infarction in Sweden
by: Kasper Johannesen, et al.
Published: (2023-03-01)

Effect of Ticagrelor Versus Clopidogrel on Aortic Stiffness in Patients With Coronary Artery Disease
by: Charalambos Vlachopoulos, et al.
Published: (2019-06-01)

A life-threatening massive hemoptysis case in the course of dual antiplatelet therapy with ticagrelor
by: Dimitrios Molyvas, et al.
Published: (2022-09-01)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01)

A Case Report of Ticagrelor-Induced Thrombocytopenia
by: Alsalman M
Published: (2023-07-01)

PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW
by: I. S. Yavelov
Published: (2017-09-01)

Hospital‐Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome
by: Aya F. Ozaki, et al.
Published: (2022-07-01)

The choice of the P2Y12 receptors blocker in the treatment of a patient with acute coronary syndrome: practice of N.I. Pirogov city clinical hospital №1
by: M. R. Atabegashvili, et al.
Published: (2019-04-01)

The Effects of Dual Antiplatelet Therapy on the Occurrence of Recurrent Cardiovascular Events After Myocardial Infarction in Obese Patients
by: Borovyk K., et al.
Published: (2019-04-01)

Efficacy and Safety of High Potent P2Y12 Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex‐Specific Systematic Review and Meta‐Analysis
by: Michelle M. Schreuder, et al.
Published: (2020-02-01)

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study
by: Jiannan Li, et al.
Published: (2020-08-01)

Timing of dual antiplatelet therapy in acute coronary syndrome: a problem of coronary artery bypass grafting accessibility for patients
by: T. S. Golovina, et al.
Published: (2020-09-01)